Stock AnaliziRhythm Holdings, Inc. IRTC
Medical/Dental Instruments · IPO 2016 · data as of November 13, 2026
iRhythm Holdings, Inc. (IRTC) is a healthcare company listed in the US with a market value of about $3.1B. In the twelve months to September 30, 2026 it had revenue of $854M and net income of -$39M, a net margin of -4.5%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 418.6, 5-year revenue growth of 23% a year, a 5-year average ROIC of -29%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 92% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $854M | $747M | $592M | $493M | $411M | $323M | $265M | $215M | $147M | $99M | $64M |
| Net income | -$39M | -$45M | -$113M | -$123M | -$116M | -$101M | -$44M | -$55M | -$50M | -$30M | -$21M |
| Free cash flow | $7M | $35M | -$31M | -$91M | -$53M | -$66M | -$27M | -$42M | -$34M | -$18M | -$19M |
| EPS (diluted) | $-1.16 | $-1.39 | $-3.63 | $-4.04 | $-3.88 | $-3.46 | $-1.58 | $-2.16 | $-2.11 | $-1.31 | $-3.95 |
| Net margin | -4.5% | -6.0% | -19.1% | -25.1% | -28.3% | -31.4% | -16.5% | -25.4% | -34.2% | -30.0% | -32.6% |
| ROIC | — | -19.4% | -50.3% | -29.1% | -24.2% | -19.9% | -7.4% | -16.4% | -41.5% | -22.2% | -11.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $153.27, 67% above the current price; targets range from $120.00 to $206.00; the consensus rating is “Strong buy”; expected EPS is $1.29 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is iRhythm stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 92% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does iRhythm pay a dividend?
Not currently.
Is iRhythm a good stock to buy?
We do not give buy or sell advice. iRhythm scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.